Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab subcutaneous in Japanese RRMS patients
NCT05265728Phase 3Terminated
- Sponsor
- Biogen
- Start
- Apr 2022
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of natalizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Primary endpoint: Cumulative Number of New Active Lesions Identified Using Brain MRI at 24 weeks. Started Apr 2022; status: terminated.
02
Drugs
natalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT05265728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05265728.